Neuroinflammation-associated activation

Neuroinflammation-associated activation refers to the upregulation and activation of CNS resident immune cells, especially microglia and astrocytes, leading to the release of pro-inflammatory mediators, cytokines, chemokines, and reactive oxygen species. These events contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, among others[2][3][4][5]. Cellular and molecular targets in this process include the NLRP3 inflammasome, cytokine and chemokine receptors (e.g., TNFR1, CCR2), and key immune signaling pathways such as NF-κB. While modulating these pathways can have therapeutic benefit, the broad process invoked by "neuroinflammation-associated activation" is not a druggable target per se but rather a descriptor for the combined effect of multiple interacting targets. This entry is best used as a conceptual category for grouping true molecular targets — such as NLRP3, TNFR1, TREM2, and specific inflammatory cytokines — rather than as a canonical target itself.

Other names

Neuroinflammatory activationactivation of neuroinflammatory pathwaysglial activation

Inhibition of pro-inflammatory cytokines production/release (e.g., TNF-α, IL-1β, IL-6); Inhibition of microglial and astrocyte activation; Inhibition of key signaling pathways (e.g., NF-κB, NLRP3 inflammasome, JNK, PI3K); Modulation of immune cell recruitment and phagocytosis